Avandia Expands Black Box With Heart Attack Risk Information
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA revises labeling for all oral anti-diabetics to include warning about the absence of conclusive evidence of cardiovascular risk.
You may also be interested in...
FDA Grants GSK's Advair Broader Use
Top-selling asthma drug cleared for COPD flare-ups.
FDA Grants GSK's Advair Broader Use
Top-selling asthma drug cleared for COPD flare-ups.
Avandia Market Share Stabilizing, GSK CEO Garnier Says
In his last earnings presentation, Garnier says it is unclear whether the type 2 diabetes drug will become a growth driver again.